Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TNXP
Strong SellSinkerTonix Pharmaceuticals Holding Corp. · Healthcare · United States · $233M · Avg Vol: $5M/d
COMPANY DESCRIPTION
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics and biologics to treat central nervous system disorders, immunology, and infectious diseases. The company's primary asset is Tonmya, a late-stage candidate for the management of fibromyalgia. Tonix operates as a high-risk, development-stage biotech player with a diversified pipeline, relying on clinical trial milestones and capital markets to fund its path to commercialization.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 7.8M | 10.1M | 13.1M | 29.9% | 29.1M | 55.0M | 110.9M | 190.9% |
| EPS | -15.68 | -16.91 | -48.59 | -14.57 | — | -13.09 | -9.95 | -7.88 | — |
| Shares | 15.9M | 15.9M | 15.9M | 12.8M | -19.8% | 17.2M | — | — | — |
| Debt | 0.8M | 9.8M | 8.1M | 1.3M | 19.9% | 1.3M | — | — | — |
| Equity | 207.2M | 105.5M | 139.6M | 245.2M | 5.8% | — | — | — | — |
| Op CF | -98.1M | -102.0M | -60.9M | -99.8M | — | -153.0M | — | — | — |
| Inv CF | -48.1M | -29.1M | -0.1M | -4.5M | — | — | — | — | — |
| Fin CF | 87.8M | 36.5M | 134.9M | 214.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TNXP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TNXP | Tonix Pharmaceuticals Holding Corp.(you) | $233M | 14 | Strong Sell |
| VYGR | Voyager Therapeutics, Inc. | $218M | 14 | Strong Sell |
| CHRS | Coherus Oncology, Inc. | $218M | 14 | Strong Sell |
| PEPG | PepGen Inc. | $213M | 14 | Strong Sell |
| KROS | Keros Therapeutics, Inc. | $219M | 16 | Strong Sell |
| SION | Sionna Therapeutics, Inc. | $265M | 14 | Strong Sell |
| ELDN | Eledon Pharmaceuticals, Inc. | $260M | 15 | Strong Sell |
| PYXS | Pyxis Oncology, Inc. | $269M | 15 | Strong Sell |
| NERV | Minerva Neurosciences, Inc. | $231M | 12 | Strong Sell |
| ABOS | Acumen Pharmaceuticals, Inc. | $211M | 13 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%